All In Biotech

Drug Trial Radar · NCT00176891

Stem Cell Transplant w/Laronidase for Hurler

Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)

Last checked: Nov 20, 2026Latest source record: Jul 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Mar 2004

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.

Conditions

  • Mucopolysaccharidosis I
  • Hurler Syndrome

Interventions

  • Stem Cell TransplantProcedure

    enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following

  • Laronidase ERTDrug

    Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Alive at One Year Post TransplantTime frame: one year
  2. Number of Patients Requiring Ventilator Support at One Year Post TransplantTime frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.